Plasma MDK in patients with breast cancer was found to be elevated compared to normal controls (ductal carcinoma in-situ, DCIS: p < 0.05; primary invasive cancer without distant metastasis: p < 0.001; metastatic disease: p < 0.00) [54]. Here, MDK is linked to ductal breast carcinoma in situ.